Amphastar Taps Private Financing After Major Eli Lilly Acquisition

US-Based Firm Looks To Raise Hundreds Of Millions After Splashing Out On Brand

Amphastar is looking to tidy up its balance sheet after the company’s landmark acquisition of Eli Lilly’s Baqsimi (glucagon) emergency nasal spray.

financing
• Source: Alamy

Generics and specialty player Amphastar Pharmaceuticals, Inc. has unveiled plans to raise approximately $300m via a private placement of senior convertible notes due in 2029, with the potential for initial purchasers to buy an additional $45m of the notes, following its recent $1bn+ deal package to acquire Eli Lilly’s Baqsimi (glucagon) emergency nasal spray.

Most of the initial capital will be designated for repaying debt and buying back stock, Amphastar said, with $200m of...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business